Letosteine
Chemical compound
- R05CB09 (WHO)
- 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid
- 53943-88-7 Y
- 68707
- DB08939 N
- 61958 Y
- 6MVF9U95DW
- D07380 Y
- CHEBI:88271 N
- Interactive image
- O=C(O)C1NC(SC1)CCSCC(=O)OCC
InChI
- InChI=1S/C10H17NO4S2/c1-2-15-9(12)6-16-4-3-8-11-7(5-17-8)10(13)14/h7-8,11H,2-6H2,1H3,(H,13,14) Y
- Key:IKOCLISPVJZJEA-UHFFFAOYSA-N Y
Letosteine is a mucolytic[1] patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy.[2] He filed his application in 2000.
References
- ^ Zhou Y, Sun S, Liu H, Cui L, Chang X, Sun Z (November 2014). "Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial". Die Pharmazie. 69 (11): 842–9. PMID 25985582.
- ^ US 6987120, del Soldato P, "Pharmaceutical compounds", issued 17 January 2006, assigned to Nicox SA
- v
- t
- e
Cough and cold preparations (R05)
- Acetylcysteine#
- Ambroxol
- Bromhexine
- Carbocisteine
- Dembrexine hydrochloride
- Domiodol
- Dornase alfa
- Eprazinone
- Erdosteine
- Letosteine
- Mannitol
- Mesna
- Neltenexine
- Sobrerol
- Stepronin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e